NASDAQ NMS - GLOBAL MARKET · CLRB
-1.56% · -$0.0400 · Vol 23.9K
After hours · updated 16:00:00 ET
Cellectar Biosciences Inc

Cellectar Biosciences Inc

Biotechnology
$2.52
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
CLRB
Cellectar Biosciences Inc
Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

72/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CLRB moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CLRB catalysts
About Cellectar Biosciences Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2005
Employees
11
Country
US

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.66
Day high
$2.66
Day low
$2.48
Previous close
$2.56
52W high
$6.17
-59.16% from high
52W low
$2.23
7% of range
Market cap
$20.5M
EPS
$-6.2700
Beta
1.69
Shares out
8M
Volume
23.9K
0.27× rel vol
Avg volume
88.7K
VWAP
$2.56
Price history computed in-house
1W
+1.61%
1M
-9.03%
3M
-23.64%
1Y
-48.25%
YTD
-14.58%
SMA 50 $2.62 · below
SMA 200 $3.05 · below
52W position 7%

CLRB overview

Veridion Score
72
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CLRB.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CLRB Form 4 filings
Public disclosures

Congress activity in CLRB

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CLRB in the cached public ledger.

Federal contracts

CLRB contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CLRB in this window.
Lobbying spend

CLRB lobbying filings, year to date.

Registered lobbying filings matched to Cellectar Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CLRB in this window.
Loading news for CLRB
Analyst ratings
Sovereign unlock shows live analyst consensus for CLRB.
Options
Sovereign unlock shows live options positioning for CLRB.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.